NasdaqGM:NAMSBiotechs
How EMA’s Positive CHMP Opinion on Ubeslo and Evlarco at NewAmsterdam Pharma (NAMS) Has Changed Its Investment Story
NewAmsterdam Pharma Company N.V. and Menarini Group recently reported that the EMA’s CHMP issued a positive opinion recommending EU-wide marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe) to treat primary hypercholesterolemia, including HeFH and mixed dyslipidemia.
This opinion, grounded in Phase 3 data showing robust LDL-C reductions with placebo-like tolerability, could be pivotal for NewAmsterdam’s royalty and milestone-based...